Related references
Note: Only part of the references are listed.Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens
Shaji Kumar et al.
BLOOD (2009)
Short-Term Thalidomide Incorporated Into Double Autologous Stem-Cell Transplantation Improves Outcomes in Comparison With Double Autotransplantation for Multiple Myeloma
Michele Cavo et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Updated survival analyses after prolonged follow-up of the phase 2, multicenter CREST study of bortezomib in relapsed or refractory multiple myeloma
Sundar Jagannath et al.
BRITISH JOURNAL OF HAEMATOLOGY (2008)
Influence of Pre- and Post-Transplantation Responses on Outcome of Patients With Multiple Myeloma: Sequential Improvement of Response and Achievement of Complete Response Are Associated With Longer Survival
Juan Jose Lahuerta et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Extended follow-up of a phase 3 trial in relapsed multiple myeloma:: final time-to-event results of the APEX trial
Paul G. Richardson et al.
BLOOD (2007)
Complete response correlates with long-term survival and progression-free survival in high-dose therapy in multiple myeloma
Helgi J. K. van de Velde et al.
HAEMATOLOGICA (2007)
Phase II Pethema trial of alternating bortezomib and dexamethasone as induction regimen before autologous stem-cell transplantation in younger patients with multiple myeloma:: Efficacy and clinical implications of tumor response kinetics
Laura Rosinol et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Long-term results of response to therapy, time to progression, and survival with lenalidomide plus dexamethasone in newly diagnosed myeloma
Martha Q. Lacy et al.
MAYO CLINIC PROCEEDINGS (2007)
International uniform response criteria for multiple myeloma
B. G. M. Durie et al.
LEUKEMIA (2006)
Predictive factors for survival in myeloma patients who undergo autologous stem cell transplantation: a single-centre experience in 211 patients
D O'Shea et al.
BONE MARROW TRANSPLANTATION (2006)
High-dose chemotherapy with autologous hematopoietic stem cell transplantation in patients with multiple myeloma
Marie A. Gertz et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2006)
Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: A clinical trial coordinated by the eastern cooperative oncology group
SV Rajkumar et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Efficacy, toxicity and feasibility of a shorter schedule of DCEP regimen for stem cell mobilization in multiple myeloma
A Corso et al.
BONE MARROW TRANSPLANTATION (2005)
Superiority of thalidomide and dexamethasone over vincristine-doxorubicin-dexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma
M Cavo et al.
BLOOD (2005)
Bortezomib or high-dose dexamethasone for relapsed multiple myeloma
PG Richardson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma
HE Oakervee et al.
BRITISH JOURNAL OF HAEMATOLOGY (2005)
Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma
S Jagannath et al.
BRITISH JOURNAL OF HAEMATOLOGY (2005)
Stem cell transplantation in multiple myeloma (0, 1, or 2)
JL Harousseau
CURRENT OPINION IN ONCOLOGY (2005)
High-dose therapy/autologous stem cell transplantation in patients with chemosensitive multiple myeloma: predictors of complete remission
E Nadal et al.
BONE MARROW TRANSPLANTATION (2004)
Drug therapy: Multiple myeloma
RA Kyle et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma
JA Child et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Mobilization of CD34+ cells in elderly patients (≥ 70 years) with multiple myeloma:: influence of age, prior therapy, platelet count and mobilization regimen
CL Morris et al.
BRITISH JOURNAL OF HAEMATOLOGY (2003)
Number of viable CD34+ cells reinfused predicts engraftment in autologous hematopoietic stem cell transplantation
DS Allan et al.
BONE MARROW TRANSPLANTATION (2002)
Thalidomide in multiple myeloma:: lack of response of soft-tissue plasmacytomas
J Bladé et al.
BRITISH JOURNAL OF HAEMATOLOGY (2001)
Graft outcome - Impact of complete remission with intensive therapy in patients with responsive multiple myeloma
R Alexanian et al.
BONE MARROW TRANSPLANTATION (2001)
Blood stem cell collections in multiple myeloma: definition of a scoring system
A Corso et al.
BONE MARROW TRANSPLANTATION (2000)
Share Paper
